The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1483
ISSUE1483
December 7, 2015
Nivolumab (Opdivo) plus Ipilimumab (Yervoy) for Metastatic Melanoma
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Nivolumab (Opdivo) plus Ipilimumab (Yervoy) for Metastatic Melanoma
December 7, 2015 (Issue: 1483)
The FDA has approved the combined use of the
programmed death receptor-1 (PD-1) blocking
antibody nivolumab (Opdivo) and the anti-CLA-4
antibody ipilimumab (Yervoy) for treatment of BRAF
V600 wild-type unresectable or metastatic melanoma.
This...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.